OncoMatch/Clinical Trials/NCT05879146
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Is NCT05879146 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nirogacestat for tumor.
Treatment: Nirogacestat — To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1500 cells/μL; Platelets ≥ 100,000 μL; Hemoglobin ≥ 9 g/dL
Kidney function
If Creatinine > 1.5 x ULN then calculated creatinine clearance must be ≥ 60 mL/min (using the Cockcroft-Gault formula)
Liver function
Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (isolated bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%); AST/ALT ≤ 2 × ULN
Cardiac function
New York Heart Association Functional Classification class 2B or better
Adequate organ and bone marrow function as defined by the following screening laboratory values: Absolute neutrophil count ≥ 1500 cells/μL; Platelets ≥ 100,000 μL; Hemoglobin ≥ 9 g/dL; Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (isolated bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%); AST/ALT ≤ 2 × ULN; If Creatinine > 1.5 x ULN then calculated creatinine clearance must be ≥ 60 mL/min (using the Cockcroft-Gault formula). Cardiac: New York Heart Association Functional Classification class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify